BODI earnings analysis
What we found in BODI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BODi reported $49.613 million of Q2 revenue and $0.11 of diluted EPS, beating consensus estimates of $49.4648 million and $(0.15), respectively. Profitability improved to $1.7 million of operating income and $6.7 million of Adjusted EBITDA, but revenue declined approximately 22.5% from $64 million in the prior-year quarter. The principal concern is the Q3 outlook for net income and adjusted net income of $(3) million to $0, alongside continued revenue contraction and $1.5 million of modeled foreign-exchange expense sensitivity.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS Beat Estimates
- Diluted EPS was $0.11 versus the consensus estimate of $(0.15), a $0.26 per-share beat.
- Revenue Beat, but Contracted YoY
- Revenue was $49.613 million, approximately 0.3% above the $49.4648 million consensus estimate, although it declined from $64 million in Q2 2025.
- Returned to Operating Profit
- The company reported $1.7 million of operating income and $6.7 million of Adjusted EBITDA, indicating a return to operating profitability in the quarter.
- Controls Remained Effective
- Management concluded that disclosure controls were effective as of June 30, 2026, and reported no changes in internal control over financial reporting during the quarter.
- Lower FX Revenue Exposure
- Foreign-currency revenue represented approximately 7% of revenue for the six months ended June 30, 2026, versus 8% in the prior-year period, and the company had no outstanding foreign-exchange options at June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Contraction Continues
- Revenue declined to $49.613 million from $64 million in Q2 2025, a decrease of approximately 22.5%, while the supplied quarterly history shows revenue falling from $54 million in Q1 2026.
- Expected Q3 Loss
- Q3 2026 outlook calls for net income and adjusted net income of $(3) million to $0, implying a potential return to losses after reported quarterly operating income of $1.7 million.
- Foreign-Exchange Sensitivity
- A hypothetical 10% change in exchange rates would increase or decrease cost of revenue and operating expenses by approximately $1.5 million; approximately 7% of six-month revenue was denominated in foreign currencies.
- No New Risk-Factor Updates
- Item 1A states there have been no material developments in the risk factors from the December 31, 2025 Form 10-K; therefore, no new or changed risk-factor disclosure was identified in this filing.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.11
- Operating margin
- 3.4%
What they said about what is next.
The report does not provide explicit EPS or revenue guidance. Management's Q3 2026 outlook, as reported with the filing, calls for net income and adjusted net income of $(3) million to $0; comparable guidance direction was not disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 12, 2026
- BODi reported Q1 2026 revenues of $54.3 million, representing a 25% decrease compared to Q1 2025. However, the company generated net income of $2.3 million, marking its third consecutive quarter of profitability, and…
- 10-K · March 10, 2026
- The 10-K frames BODi as a pivoting, subscription-led fitness & nutrition platform with 0.9 million digital subscriptions and a product roadmap that includes a retail rollout in 2026 (Shakeology in H1 2026). Engagement…
- 10-Q · November 10, 2025
- BODi reported Q3 2025 results with revenue of $59.887 million, exceeding expectations and up from $60 million in Q2 2025, but represents a significant decline from $102.193 million a year ago. Net income turned positive…
- 10-Q · August 7, 2025
- BODi reported Q2 revenue of $63,941,000 (down from $110,183,000 in Q2 2024) with gross margin of 72.3% and an operating loss of $3,964,000. Net loss per share improved to $(0.85) from $(1.59) a year earlier, and cash &…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BODI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever